On-demand Webinar
Beyond the Prescription: Why GLP-1s Require a Complete Metabolic Care Model
Webinar summary
GLP-1 medications are transforming the treatment of obesity and metabolic disease—but for many employers, expanded access has not yet translated into sustainable outcomes. As utilization rises, organizations are grappling with how to ensure appropriate prescribing, support long-term adherence, and ultimately drive meaningful clinical and financial impact.
The challenge is clear: medication alone is not enough. Without integrated support across navigation, prescribing, and behavior change, many GLP-1 strategies fall short of their potential. A more complete, coordinated model is required to bridge the gap between access and outcomes.
Joined by Richard Frank and Ted Feldman, this discussion explored how employers could move beyond the prescription to build more effective GLP-1 strategies. Moderated by Brad Bare, the session examined how aligning pharmacy navigation, clinician oversight, and whole-person metabolic care could improve engagement, adherence, and long-term success.
Drawing on early insights from newly launched employer programs, speakers shared what was emerging across enrollment, activation, and member engagement—and what these signals suggested about the future of GLP-1 care.
Key takeaways:
- Why access alone is insufficient for achieving sustainable GLP-1 outcomes
- How integrated models that connect navigation, prescribing, and behavior change improve adherence and engagement
- Early indicators from employer populations, including enrollment and engagement trends, that signal long-term success
- Actionable strategies to design more complete, effective GLP-1 care models that balance cost, experience, and outcomes
